Onartuzumab  (Synonyms: 奥那妥组单抗; MetMAb)

Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET^[1].
Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1133766-06-9

液体

Colorless to light yellow

奥那妥组单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  (Fab-G1-kappa)-(Fc-G1)

• 
  Immobilized Onartuzumab can bind Human c-MET/HGFR Protein (ECD, His Tag). The EC₅₀ for this effect is 4.21 ng/mL.

• [1]. Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96.  [Content Brief]

  [2]. Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165(1):186-197.  [Content Brief]